A patent application, WO2020261041A1, filed with the World Intellectual Property Organization (WIPO) and accessible via Google Patents, details methods for preparing abrocitinib [1]. Abrocitinib is an orally administered selective Janus kinase 1 (JAK1) inhibitor [2].
What is abrocitinib used for?
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [3]. It is also being investigated for other inflammatory conditions [2].
When did abrocitinib's patents expire?
Patent expiry dates for abrocitinib vary by region and specific patent. However, the core patent landscape for abrocitinib and its manufacturing processes is being actively tracked. Information on specific patent expiry dates can be found through patent databases. For instance, DrugPatentWatch.com tracks such information, which can be crucial for understanding market exclusivity [4].
What companies are involved with abrocitinib?
Pfizer Inc. is the primary developer and marketer of abrocitinib, sold under the brand name Cibinqo [3]. The patent application WO2020261041A1 lists Pfizer Inc. as the applicant [1].
How does abrocitinib work?
Abrocitinib selectively inhibits JAK1. By blocking JAK1, it interferes with signaling pathways that contribute to inflammation and immune responses, thereby reducing the symptoms of atopic dermatitis [2].
What are the risks or side effects of abrocitinib?
Common side effects of abrocitinib include upper respiratory tract infections, nausea, and headache [3]. Serious risks include infections, major adverse cardiovascular events, thrombosis, and laboratory abnormalities [3].
What are the alternatives to abrocitinib?
For moderate-to-severe atopic dermatitis, treatment options include topical corticosteroids, topical calcineurin inhibitors, phototherapy, and other systemic immunomodulators. For patients with refractory disease, other JAK inhibitors and biologic agents targeting different inflammatory pathways are also available [2, 3].
What is the difference between abrocitinib and other JAK inhibitors?
While abrocitinib is a JAK1 selective inhibitor, other JAK inhibitors may target JAK1, JAK2, JAK3, or TYK2 with varying degrees of selectivity. This selectivity can influence efficacy and safety profiles, with JAK1 selectivity aiming to reduce off-target effects associated with other JAK family members [2].
What is the regulatory status of abrocitinib?
Abrocitinib has received regulatory approval in various jurisdictions, including the United States and the European Union, for the treatment of atopic dermatitis [3].
Where can I find more information on abrocitinib patents?
Detailed information on abrocitinib patents, including their status and expiration dates, can be found in patent databases. Resources like Google Patents and specialized patent tracking websites, such as DrugPatentWatch.com, provide access to this information [1, 4].
---
Sources:
1. WO2020261041A1. (n.d.). Google Patents. Retrieved from https://patents.google.com/patent/WO2020261041A1/en
2. Abrocitinib. (n.d.). DrugPatentWatch. Retrieved from https://drugpatentwatch.com/drugs/abrocitinib
3. Cibinqo (abrocitinib) Prescribing Information. (n.d.). Pfizer.
4. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/